In response to concerns that Merck’s $5.7 billion diabetes drug Januvia could be carcinogenic…
“Merck said in a statement today it’s willing to participate in an independent review of data called for by the American Diabetes Association.”
The full story here:
bloomberg.com/news/2013-06-1 … drugs.html
In all fairness, Merck is to be applauded.
Now let’s hope they see the light on the finasteride front and embrace third-party clinical studies seeking to determine the root causes of post-finasteride syndrome, and subsequently developing therapies for this devastating condition that is devastating the lives of thousands of men the world over.